MX2019009027A - Algoritmos y metodos para evaluar criterios de valoracion tardios en cancer de prostata. - Google Patents

Algoritmos y metodos para evaluar criterios de valoracion tardios en cancer de prostata.

Info

Publication number
MX2019009027A
MX2019009027A MX2019009027A MX2019009027A MX2019009027A MX 2019009027 A MX2019009027 A MX 2019009027A MX 2019009027 A MX2019009027 A MX 2019009027A MX 2019009027 A MX2019009027 A MX 2019009027A MX 2019009027 A MX2019009027 A MX 2019009027A
Authority
MX
Mexico
Prior art keywords
prostate cancer
algorithms
methods
clinical endpoints
late clinical
Prior art date
Application number
MX2019009027A
Other languages
English (en)
Inventor
Crager Michael
Maddala Tara
Lu Ruixiao
Febbo Phillip
Jeffrey Lawrence Hugh
Zhang Nan
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2019009027A publication Critical patent/MX2019009027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Image Processing (AREA)

Abstract

La presente descripción se refiere a los usos de un algoritmo para la Puntuación de Próstata GenómicaTM con base en la expresión de genes múltiples (GPSTM) para evaluar las varias evaluaciones clínicas en pacientes con cáncer de próstata, tales como riesgos de recurrencia clínica (CR), recurrencia bioquímica (BCR), metástasis distante (Mets), y muerte por cáncer de próstata (PCD). En algunas modalidades, el resultado de la GPS se determina para pacientes con cáncer de próstata de bajo intermedio riesgo con el fin de ayudar en la determinación de las estrategias del tratamiento para esos pacientes.
MX2019009027A 2017-02-13 2018-02-12 Algoritmos y metodos para evaluar criterios de valoracion tardios en cancer de prostata. MX2019009027A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762458474P 2017-02-13 2017-02-13
US201762473204P 2017-03-17 2017-03-17
US201762578622P 2017-10-30 2017-10-30
PCT/US2018/017790 WO2018148642A1 (en) 2017-02-13 2018-02-12 Algorithms and methods for assessing late clinical endpoints in prostate cancer

Publications (1)

Publication Number Publication Date
MX2019009027A true MX2019009027A (es) 2020-01-27

Family

ID=61283339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009027A MX2019009027A (es) 2017-02-13 2018-02-12 Algoritmos y metodos para evaluar criterios de valoracion tardios en cancer de prostata.

Country Status (14)

Country Link
US (1) US20200040400A1 (es)
EP (1) EP3580357B1 (es)
JP (1) JP7239477B2 (es)
KR (1) KR102376220B1 (es)
CN (1) CN110291206A (es)
AU (1) AU2018219354B2 (es)
BR (1) BR112019016652A2 (es)
CA (1) CA3049844C (es)
CO (1) CO2019008649A2 (es)
ES (1) ES2914727T3 (es)
IL (1) IL267911B2 (es)
MX (1) MX2019009027A (es)
SG (2) SG10201912097QA (es)
WO (1) WO2018148642A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019221930A1 (en) * 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes
CN109306867B (zh) * 2018-11-19 2022-04-05 中国石油天然气股份有限公司 一种冲积扇沉积储层构型单元自动识别方法
CN115427811A (zh) * 2020-04-23 2022-12-02 日兴生物科技有限公司 前列腺癌诊断的相关方法
KR102497196B1 (ko) 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
ES2373686T3 (es) 2005-06-23 2012-02-07 Biocartis Sa Cartucho, sistema y procedimiento para diagnósticos médicos automatizados.
EP2407554A1 (en) * 2010-07-14 2012-01-18 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Methods and kits for the diagnosis of prostate cancer
EP2809812A4 (en) 2012-01-31 2016-01-27 Genomic Health Inc GENE EXPRESSION PROFILE ALGORITHM AND PROSTATE CANCER PROGNOSTIC DETERMINATION TEST
US9200328B1 (en) * 2012-03-14 2015-12-01 New York University Methods and kits for diagnosing the prognosis of cancer patients
DK3303618T3 (da) * 2015-05-29 2019-12-16 Koninklijke Philips Nv Fremgangsmåder til prognose af prostatacancer

Also Published As

Publication number Publication date
CA3049844A1 (en) 2018-08-16
SG10201912097QA (en) 2020-02-27
US20200040400A1 (en) 2020-02-06
JP2020507320A (ja) 2020-03-12
ES2914727T3 (es) 2022-06-15
CN110291206A (zh) 2019-09-27
EP3580357B1 (en) 2022-04-27
IL267911B2 (en) 2023-08-01
JP7239477B2 (ja) 2023-03-14
EP3580357A1 (en) 2019-12-18
WO2018148642A1 (en) 2018-08-16
BR112019016652A2 (pt) 2020-03-31
AU2018219354B2 (en) 2024-06-27
KR20190113814A (ko) 2019-10-08
CA3049844C (en) 2022-06-28
CO2019008649A2 (es) 2019-10-31
IL267911B1 (en) 2023-04-01
AU2018219354A1 (en) 2019-07-25
SG11201906318WA (en) 2019-08-27
IL267911A (en) 2019-09-26
KR102376220B1 (ko) 2022-03-21

Similar Documents

Publication Publication Date Title
MX2019009027A (es) Algoritmos y metodos para evaluar criterios de valoracion tardios en cancer de prostata.
MX2020009704A (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
WO2019028285A3 (en) Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
EP2596132A4 (en) METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
MY182773A (en) Method for indicating a presence or non-presence of aggressive prostate cancer
MX2018006781A (es) Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
WO2014152777A3 (en) Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2015158652A3 (en) S1 oop and hyluronic acid as biomarkers for metastatic breast cancer
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
GB201018312D0 (en) Metagene expression signature for prognosis of breast cancer patients
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли
WO2010093907A3 (en) An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1
AU2019268079A1 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
ES2640524A1 (es) Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas
Loeb PDE5 inhibitors: no increased risk of prostate cancer recurrence
WO2013190468A3 (en) Computer-based predictor for prostate cancer
WO2014160876A3 (en) Brca2-specific modifier locus related to breast cancer risk